Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.

8,234 shares were sold for a transaction value of ~$154,000, with weighted average pricing around $18.74 per share on March 4–6, 2026. This sale reduced Mazumdar's direct Common Stock holdings to 339,392 shares post-transaction.